We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current 0RDB market cap is 166.54M. The company's latest EPS is EUR -0.0549 and P/E is -49.54.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 42k | 98k | 168k | 255k | 153k |
| Operating Income | -3.83M | -4.29M | -7.01M | -5.49M | -4.55M |
| Net Income | -3.68M | -3.4M | -4.69M | -4.23M | -3.35M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 80.09M | 94.11M | 95.38M | 103.7M | 106.9M |
| Total Liabilities | 18.97M | 18.18M | 24.12M | 31.13M | 25.13M |
| Total Equity | 61.13M | 75.93M | 71.26M | 72.57M | 81.78M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | -3.93M | -4.82M | -3.63M | -1.85M | -575k |
| Investing | -9.58M | -9.08M | -11.72M | -14.27M | -14.5M |
| Financing | 14.26M | 18.38M | 4.12M | 8.71M | 6.02M |
| Market Cap | 166.54M |
| Price to Earnings Ratio | -49.54 |
| Price to Sales Ratio | 1.09k |
| Price to Cash Ratio | 13.57 |
| Price to Book Ratio | 2.03 |
| Dividend Yield | - |
| Shares Outstanding | 61.12M |
| Average Volume (1 week) | 279 |
| Average Volume (1 Month) | 680 |
| 52 Week Change | 0.00% |
| 52 Week High | 2.725 |
| 52 Week Low | 2.725 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Oryzon Genomics Sa |
| Address |
carrera de san jeronimo 15 madrid, community of madrid 08940 |
| Website | https://www.oryzon.com |
| Industry | med, dental, hosp eq-whsl (5047) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
